Treatments for relapsing, refractory multiple myeloma: A health technology assessment
Project
|Last update
Evaluation of the clinical and cost-effectiveness of the increasing number of treatments available for patients who experience relapsed or refractory multiple myeloma (RRMM).
Summary
Multiple myeloma (MM), the second most common type of blood cancer, reduces the body’s ability to fight infection and can lead to anemia, bone damage, nerve damage, kidney damage, etc. Approximately 450 Norwegians are diagnosed with myeloma annually. Because there is currently no cure for myeloma, it is important to evaluate the clinical and cost-effectiveness of the increasing number of treatments available for patients who experience relapsed or refractory multiple myeloma (RRMM).
Project leader
Arna Sue Desser, Norwegian Institute of Public Health
Project participants
Fredrik Schjesvold, Oslo University Hospital
Mats Irgen Olsen, University Hospital of North Norway
Olav Ljøsne, The norwegian Leukemia Association
Einar Haukås, Stavanger Hospital Trust - Stavanger University Hospital
Ulrikke Højslev Lund, Norwegian Institute of Public Health
Christopher James Rose, Norwegian Institute of Public Health
Gunn Eva Næss, Norwegian Institute of Public Health
Elisabet Vivianne Hafstad, Norwegian Institute of Public Health
Anna Lien Espeland, Norwegian Institute of Public Health
Liv Giske, Norwegian Institute of Public Health
Ingrid Kristine Ohm, Norwegian Institute of Public Health
About the project
Start
30.03.2020
End
30.06.2021
Status
Active
Project owner/ Project manager
Norwegian Institute of Public Health